Nimotuzumab with immunotherapy and chemotherapy for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with squamous cell carcinoma of the head and neck (stages III–IVB), confirmed by biopsy
- Your tumor can be surgically removed, as determined by a team of cancer specialists
- Good overall health (ECOG performance status 0–1: able to carry out daily activities)
- Blood counts, kidney function, and liver function are adequate for chemotherapy
- Not pregnant or breastfeeding; willing to use effective birth control during and for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (nimotuzumab and adebrelimab) along with chemotherapy for people with head and neck cancer that has returned or spread, and who cannot take the standard chemo drug cisplatin. The goal is to see if this combination works and is safe for these patients.
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
This trial tests a drug called nimotuzumab combined with radiation therapy for older adults (65+) with advanced head and neck cancer. It aims to help control the cancer when chemotherapy is not an option.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This study tests whether adding two different drugs (nimotuzumab and benmelstobart) to standard radiation therapy after surgery can help improve outcomes for people with intermediate-risk head and neck cancer. It looks at whether the combination slows cancer growth or reduces the chances of it coming back.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.